Abstract
Atrophie blanche was originally attributed to syphilis or tuberculosis, but recent investigators have generally implicated a localized cutaneous vasculitis. In an attempt to inhibit the occlusive vascular changes believed responsible for the cutaneous lesions, drugs such as phenformin and ethylestrenol, which increased the blood fibrinolytic activity, were used with favorable results. When phenformin was taken off the market, the use of drugs that act by preventing platelet aggregation was suggested by encouraging results in the management of other occlusive vascular disorders such as coronary artery disease and stroke. Excellent results are reported in two cases of atrophie blanche treated with two anti-platelet-aggregating medications, aspirin and dipyridamole (Persantine). It is imperative that low doses of aspirin be used, since high doses have the effect of increasing the thrombotic tendency by preventing prostacyclin formation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
